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Chronic obstructive pulmonary disease (COPD) is a common disease
in adults over 40 years of age and has a great social and economic
impact. It remains little recognized and undertreated even in devel-
oped countries. However, there are no data about its diagnosis and
treatment in Brazil. The objectives of the present study were to
evaluate the proportion of COPD patients who had never been diag-
nosed and to determine if the COPD patients who had been identified
were receiving appropriate treatment. The Latin American Project for
the Investigation of Obstructive Lung Disease (PLATINO) was a
randomized epidemiological study of adults over 40 years living in
five metropolitan areas, including São Paulo. The studied sample was
randomly selected from the population after a division of the metro-
politan area of São Paulo in clusters according to social characteris-
tics. All subjects answered a standardized questionnaire on respiratory
symptoms, history of smoking, previous diagnosis of lung disease,
and treatments. All subjects performed spirometry. The criterion for
the diagnosis of COPD was defined by a post-bronchodilator FEV1/
FVC ratio lower than 0.7. A total of 918 subjects were evaluated and
144 (15.8%) met the diagnostic criterion for COPD. However, 126
individuals (87.5%) had never been diagnosed. This undiagnosed
group of COPD patients had a lower proportion of subjects with
respiratory symptoms than the previously diagnosed patients (88.9 vs
54.8%) and showed better lung function with greater FEV1 (86.8 ±
20.8 vs 68.5 ± 23.6% predicted) and FVC (106.6 ± 22.4 vs 92.0 ±
24.1% predicted). Among the COPD patients, only 57.3% were
advised to stop smoking and 30.6% received the influenza vaccine. In
addition, 82.3% did not receive any pharmacological treatment. In
conclusion, COPD is underdiagnosed and a large number of COPD
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Introduction
Chronic obstructive pulmonary disease
(COPD) is a respiratory disease character-
ized by chronic airflow obstruction, which is
not totally reversible, is generally progres-
sive and is associated with an abnormal in-
flammatory response of the lungs to the
inhalation of particles and toxic gases (1).
COPD includes two entities, i.e., chronic
bronchitis and emphysema. A diagnosis
should be considered in any individual over
40 years old presenting respiratory symp-
toms and/or a history of exposure to risk
factors, particularly smoking. According to
the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines, COPD
diagnosis is based on a post-bronchodilator
forced expiratory volume in 1 s (FEV1)  over
forced vital capacity (FEV1/FVC) ratio lower
than 0.7 (1).
Until the recent publication of data from
the PLATINO Study (Latin American Project
for the Investigation of Obstructive Lung
Disease; 2,3), the only population study on
the prevalence of chronic bronchitis in Bra-
zil was performed in Pelotas (RS) and was
based only on respiratory symptoms. The
prevalence of chronic bronchitis was 12.7%
(4). The PLATINO Study was performed in
order to assess COPD prevalence by means
of home spirometry in individuals over 40
years of age living in five large metropolitan
areas in Latin America (São Paulo, Montevi-
deo, Santiago, Caracas, and Mexico City).
In Brazil, COPD prevalence was 15.8%
(95%CI = 13.5-18.1), according to a post-
bronchodilator FEV1/FVC ratio lower than
0.7. Apart from its high prevalence, COPD is
a disease of great social and economic impact
(5). In 2005, more than 174,000 patients were
admitted to hospitals covered by the Unified
Health System (Sistema Único de Saúde) and
diagnosed as having COPD, with the disease
resulting in over 30,000 deaths (6).
COPD is underestimated and underdiag-
nosed globally (7,8), but no statistics about
the disease are available for Brazil. Since
COPD has a high social and economic im-
pact, the information regarding the undiag-
nosed proportion of these patients may pro-
duce data to be used by health authorities in
our country to improve COPD management.
COPD therapy has been well-established
and is divided into pharmacological and non-
pharmacological treatments (1,9,10). Phar-
macological treatment includes the use of
inhalatory bronchodilators and corticoste-
roids, stratified according to the stage of the
disease, as determined by FEV1. Among
non-pharmacological treatments, the two
most important measures are smoking ces-
sation and vaccination against influenza.
However, it is not known how these guide-
lines are followed in Brazil. The objectives
of the present study were to evaluate the
proportion of undiagnosed COPD patients
among São Paulo PLATINO Study patients,




The study was approved by the Ethics
and Research Committee of Universidade
Federal de São Paulo (Unifesp), São Paulo,
SP, Brazil, and was based on data collected
by the PLATINO Study. Methods and re-
sults on COPD prevalence in Latin America
have been previously published (2,3). The
PLATINO Study was a transverse study un-
dertaken in order to evaluate COPD preva-
lence and risk factors in five large metro-
politan areas of Latin America, and the São
Paulo metropolitan area was chosen in Bra-
zil. The sample studied was selected in sev-
eral stages. The metropolitan area was first
stratified into the main city and surrounding
municipalities. These two subsets were fur-
ther stratified by socioeconomic status. We
selected 68 census tracts at each site, taking
stratification into account and using a prob-
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ability of selection proportional to the num-
ber of households in each tract. Within each
tract, we counted the number of people in
each household and every count was up-
dated from the most recent census. We chose
an average of 15 households using system-
atic sampling within each tract. All adults
aged 40 years or more living in the selected
households were invited to participate and
were submitted to the evaluations in their
own homes after signing an informed con-
sent form to participate in the study. Sample
size calculations suggested that 800 people
would be needed in each area to estimate a
prevalence of up to 30% with a margin of
error of less than 4 percentage points. We
aimed to locate about 1020 eligible partici-
pants per site, with a predicted 20% refusal
rate.
All interviews and examinations took
place at home, and proxy information was
not accepted. We obtained data about sev-
eral factors potentially associated with COPD
using a questionnaire that included sections
of the American Thoracic Society Division
of Lung Diseases (ATS/DLD) (11), Euro-
pean Community Respiratory Health Sur-
vey II (12), and Lung Health Study (13)
instruments. Questions were related to respi-
ratory symptoms, previous diagnosis of pul-
monary diseases, influenza vaccination
within the previous year, educational infor-
mation on smoking cessation, and previous
pharmacological treatments. We measured
height with a portable stadiometer (Seca®,
Curitiba, PR, Brazil; precision 0.1 cm).
Weight was measured with an electronic
scale (Tanita®, Curitiba, PR, Brazil; preci-
sion 200 g). Pre- and post-bronchodilator
spirometry was performed (Easy-One®, NDD
Medical Technologies, Chelmsford, MA,
USA, and Zurich, Switzerland).
Diagnosis of chronic obstructive pulmonary
disease
COPD diagnosis was based on a post-
bronchodilator FEV1/FVC ratio lower than
0.7 and COPD stage was determined using
the most recent version of the GOLD guide-
lines (14).
Definition of previous diagnosis of
pulmonary emphysema, chronic bronchitis
and COPD
The three principal questions that identi-
fied a previous diagnosis of pulmonary em-
physema, chronic bronchitis and COPD were:
1) “Has your health provider told you that
you have lung emphysema?”; 2) “Has your
health provider told you that you have chronic
bronchitis?”, and 3) “Has your health pro-
vider told you that you have chronic obstruc-
tive pulmonary disease (COPD)?”. The ab-
sence of a previous diagnosis of emphy-
sema, chronic bronchitis and COPD was
considered wherever the subject answered
“no” to any of these questions and presented
an FEV1/FVC ratio lower than 0.7 as as-
sessed by spirometry.
Evaluation of non-pharmacological treatment
of COPD
Smoking cessation and influenza vaccina-
tion were determined by means of the follow-
ing questions: 1) “Has your health provider at
any time advised you to stop smoking?”, and
2) “Have you taken the influenza vaccination
within the last 12 months?”.
Evaluation of pharmacological treatment of
COPD
Pharmacological treatment was defined
as active when the answer to the question
“Have you taken any lung or breathing medi-
cation within the last 12 months?” was “yes”.
Statistical analysis
The group of COPD patients was divided
into two subgroups: those previously diag-
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nosed as having COPD and those undiag-
nosed. The two groups were comparable in
terms of demographic data and use of phar-
macological and non-pharmacological treat-
ment. The numerical data in the descriptive
analysis are reported as means ± SD. Cat-
egorical variables are presented as absolute
numbers and as a percentage of the total.
FEV1 and FVC are reported as percentages
of predicted values for age and height. COPD
patients were stratified into stages I, II, III,
and IV according to disease severity based
on GOLD guidelines. For statistical analy-
sis, stages III and IV were grouped together.
The mean values of the numerical variables
were compared between groups by the Stu-
dent t-test. Comparison of the proportion of
the categorical variables between independ-
ent groups was performed by the chi-square
test. The level of significance was set at P <
0.05 in all analyses.
Results
A total of 984 individuals were inter-
viewed. However, 21 refused to perform the
spirometry test, and 45 individuals did not
perform the post-bronchodilator spirometry.
Thus, a total sample of 918 individuals was
submitted to pre- and post-bronchodilator
spirometry. Of these 918 individuals, 144
(15.8%) presented an FEV1/FVC ratio lower
than 0.7 and were characterized as COPD
patients. The demographic data of these
COPD patients are presented in Table 1.
This sample of COPD patients consisted of
50.7% males, 59% Caucasians, with a mean
age of 59.7 years and a mean schooling of 5
years. The total group of COPD patients
included 51 individuals who were current
smokers (35.4%), 45 former smokers (31.3%)
and 48 non-smokers (33.3%), with a mean
cigarette consumption equal to 18.9 packs/
year. Concerning the pulmonary function
values, the mean FEV1/FVC ratio for the
total sample of COPD patients was 0.62;
mean FEV1 was 84.5% of predicted and
mean FVC was 104.7% of predicted. The
stratification of COPD patients into stages
according to the GOLD guidelines was as
follows: 62.5% in stage I, 29.9% in stage II,
and 7.6% in stages III and IV.
Evaluation of a previous diagnosis of lung
emphysema, chronic bronchitis and COPD
Only 3 of the COPD patients studied
(2.1%) had received a previous diagnosis of
lung emphysema, 15 (10.4%) had received a
diagnosis of chronic bronchitis and 3 (2.1%)
a diagnosis of COPD. When the three diag-
noses were grouped, only 18 individuals
(12.5%) had been previously diagnosed as
COPD patients (Table 2). When lung func-
tion was compared between the previously
Table 1. Demographic characteristics of 144 sub-





Age (years) 59.7 ± 11.6





Current smoker 51 (35.4%)
Former smoker 45 (31.3%)
Non-smoker 48 (33.3%)
Smoking consumption 18.9 ± 23.5
(packs/year)
Spirometry
FEV1/FVC 0.62 ± 0.09
FVC (% predicted) 104.7 ± 23.1
FEV1 (% predicted) 84.5 ± 21.9
COPD stage
Stage I 90 (62.5%)
Stage II 43 (29.9%)
Stages III and IV 11 (7.6%)
Data are reported as means ± SD or number of
subjects with percent in parentheses. COPD =
chronic obstructive pulmonary disease; FEV1 =
forced expiratory volume in 1 s; FVC = forced vital
capacity.
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diagnosed COPD and undiagnosed COPD
groups, the latter was found to present a
higher FEV1/FVC ratio (0.62 ± 0.08 vs 0.57
± 0.12), higher FEV1 (86.8 ± 20.8 vs 68.5 ±
23.6% predicted) and FVC (106.6 ± 22.4 vs
92.0 ± 24.1% predicted), which indicate bet-
ter lung function. Individuals in stages I and
II comprised the largest percentage of undi-
agnosed individuals, 92.2 and 86.0%, re-
spectively, while individuals in stages III
and IV presented a smaller proportion of
undiagnosed individuals (54.5%), with a sta-
tistically significant difference between them
(Table 2). Variables such as gender, age,
schooling, race, marital status, and smoking
consumption were not statistically different
between the two groups. However, when
respiratory symptoms were evaluated, it was
observed that the previously diagnosed
COPD group presented a greater proportion
of patients with respiratory symptoms in
comparison with the undiagnosed group:
chronic cough (44.4 vs 9.5%), dyspnea (72.2
vs 34.9%), wheezing (77.8 vs 34.9%), and a
combination of any symptoms (88.9 vs
54.8%), all of them with statistically signifi-
cant differences (Figure 1). There was no
statistically significant difference in expec-
toration between the two groups. Other char-
acteristics such as gender, age, schooling,
skin color, smoking status, and smoking con-
sumption did not differ between groups
(Table 2).
Evaluation of non-pharmacological treatment
Of the 96 smokers or former smokers in
the group of COPD patients, only 55 (57.3%)
had been advised to stop smoking. When the
groups of previously diagnosed and undiag-
nosed individuals were compared, no statis-
tical difference was observed (Table 3).
When COPD patients were asked about in-
fluenza vaccination during the previous year,
only 44 individuals (30.6%) reported that
they had been immunized. No significant
difference was observed between previously
Table 2. Comparison of the demographic data between subjects with and without a
diagnosis of chronic obstructive pulmonary disease (COPD).
Variables Previously diagnosed Undiagnosed
COPD group COPD group
N 18 (12.5%) 126 (87.5%)
Gender
Male 7 (38.9) 66 (52.4)
Female 11 (61.1) 60 (47.6)
Age (years) 60.5 ± 14.0 59.6 ± 11.3
Schooling (years) 3.7 ± 3.4 5.2 ± 5.2
Skin color
Caucasian 9 (50.0%) 76 (60.3%)
Non-Caucasian 9 (50.0%) 50 (39.7%)
Smoking status
Current smoker 4 (22.2%) 47 (37.3%)
Former smoker 6 (33.3%) 39 (31.0%)
Non-smoker 8 (44.5%) 40 (31.7%)
Smoking consumption (packs/year) 14.3 ± 21.3 19.6 ± 23.8
Spirometry
FEV1/FVC 0.57 ± 0.12 0.62 ± 0.08*
FVC (% predicted) 92.0 ± 24.1 106.6 ± 22.4*
FEV1 (% predicted) 68.5 ± 23.6 86.8 ± 20.8*
COPD stage
Stage I 7 (7.8%) 83 (92.2%)*
Stage II 6 (13.9%) 37 (86.1%)
Stages III and IV 5 (45.5%) 6 (54.5%)
Data are reported as means ± SD or number of subjects with percent in parentheses.
For abbreviations, see legend to Table 1.
*P < 0.05 compared to previously diagnosed COPD group (Student t-test or chi-
square test).
Figure 1. Comparison of the oc-
currence of symptoms between
the group with a previous diagno-
sis of chronic obstructive pulmo-
nary disease (COPD; open col-
umns) and undiagnosed COPD
subjects (filled columns). NS =
non-significant (chi-square test).
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diagnosed and undiagnosed individuals
(Table 3).
Evaluation of pharmacological treatment
When individuals were questioned about
the use of lung medication within the previ-
ous 12 months, only 24 in the group of
COPD patients (16.7%) reported that they
had received medication (Table 3). Con-
cerning the whole group of COPD patients,
82 individuals in stage I (91.2%), 32 in stage
II (74.4%) and 6 in stages III and IV (54.5%)
had not received any medication within the
previous year. Among the previously diag-
nosed COPD group, only nine had used
medication within the previous year (50%).
On the other hand, in the undiagnosed COPD
groups only 15 individuals (11.9%) had re-
ceived treatment, with a statistically signifi-
cant difference (P = 0.001).
Discussion
As far as we know, this is the first study
performed in Brazil in order to assess previous
diagnosis and therapeutic approach to COPD
patients. These results came from the
PLATINO Study, which was the first popula-
tion-based study on the prevalence and impact
of COPD in large metropolitan regions of five
countries of Latin America (2,3).
Due to the high mortality and the high
cost of COPD management and treatment in
its most advanced stages, early identifica-
tion of COPD and appropriate treatment are
of the utmost importance to prevent these
stages from being reached. It has been re-
ported that the absence of diagnosis of air-
flow limitation is very common in the gen-
eral population (15). In the present study,
87.5% of the individuals diagnosed with
COPD by the PLATINO Study indicated
that they had never been diagnosed previ-
ously. However, the low proportion of undi-
agnosed individuals is not exclusive to Bra-
zil, with a 40% rate in Sweden (16) and a
78.2% rate in Spain (17). In the present
study, we observed that undiagnosed COPD
patients presented better lung function and
fewer respiratory symptoms (chronic cough,
dyspnea and wheezing). These data are in
accordance with those of other studies. In a
Dutch study, it was reported that the absence
of diagnosis was associated with a lower
smoking load, absence of dyspnea and ex-
pectoration (18). On the other hand, a his-
tory of smoking and wheezing may be a
good predictor of airflow obstruction (19).
However, it is difficult to diagnose COPD in
its moderate stage on the grounds of clinical
evaluation alone without spirometry (20-22)
because COPD symptoms are mostly non-
specific and the diagnosis may be delayed.
Respiratory symptoms such as chronic cough
and expectoration very often are not consid-
ered to be important by the patients and may
even be neglected by physicians for years. In
addition, COPD patients are only diagnosed
when they seek medical care, a fact that
normally occurs when they are breathless
after their daily efforts (23-26). Thus, be-
cause of some factors such as slow progres-
sion of the disease, the patients may not
consider symptoms to be important and the
low sensitivity of a clinical examination for
the diagnosis of the disease impairs the diag-
nosis of COPD. Although the clinical fea-
tures are very important in cases in which
COPD is suspected, spirometry is the gold
standard for the diagnosis and should be
performed.
Table 3. Proportion of subjects with and without a previous diagnosis of chronic
obstructive pulmonary disease (COPD) who received non-pharmacological or phar-
macological treatment.
Treatment All COPD Previously diagnosed Undiagnosed
subjects COPD group COPD group
Smoking cessation 55 (57.3%) 7 (70.0%) 48 (55.8%)
Influenza vaccination 44 (30.6%) 6 (33.3%) 38 (30.2%)
Pharmacological treatment 24 (16.7%) 9 (50.0%) 15 (11.9%)*
Data are reported as means ± SD or number of subjects with percent in parentheses.
*P < 0.001 compared to the previously diagnosed COPD group (chi-square test).
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When COPD patients stop smoking there
may be a reduction in the decline of lung
function (27). The proportion of smoking
COPD patients who had received any advice
on smoking cessation was low (57.3%), lower
than rates observed in two international stud-
ies, where it was approximately 70% (28,29).
However, the design of these two studies
differed from that of the PLATINO Study:
one of them evaluated patients who were
admitted to hospitals due to COPD exacer-
bation (28) and the other evaluated primary
health care services (29). Thus, the PLATINO
Study results reflect the actual approach to
COPD patients in the community and show
that advice on smoking cessation should be
more widespread in our country.
Vaccination against influenza may re-
duce morbidity and mortality in COPD pa-
tients (30) and should be administered to
everyone with the disease, regardless of age.
A Spanish study showed that of the indi-
viduals who were admitted to hospitals due
to COPD exacerbation, 28% had not been
vaccinated against influenza (31); a similar
finding was also reported in the United States
(32).
Our results showed that 83.3% of the
COPD patients had not been receiving any
pharmacological treatment over the last year.
In Spain, it was reported that only 19.3% of
COPD patients were receiving any drug treat-
ment. In addition, less than half of the severe
and very severe cases (FEV1 <50%) were
receiving any treatment for respiratory dis-
ease (17). The recommendations for phar-
macological treatment are not dependent on
the presence of symptoms. All moderate,
severe and very severe patients (FEV1 less
than 80%) according to the Brazilian Con-
sensus in COPD (10), GOLD (14) or ATS/
ERS Guidelines (9) are advised to receive
pharmacological treatment continuously.
This situation was also common in other
studies performed in Europe. In a British
study, it was shown that only 36.9% of the
individuals affected by respiratory diseases
(asthma or COPD) used bronchodilators or
inhalatory corticosteroids (33). These data
show that the low rate of COPD patients
under treatment is not an exclusive feature
of Brazil. Our study has demonstrated that
COPD patients do not usually receive the
recommended pharmacological and non-
pharmacological treatments. The most plau-
sible reason for this may be related to the
absence of a COPD diagnosis, as shown in
the previously diagnosed COPD group which
presented a higher proportion of subjects
receiving pharmacological treatment (Table
3). If the patients have not been diagnosed,
they will not be treated. In addition, the
underdiagnosed group presented a smaller
proportion of respiratory symptoms, which
may have been responsible for the underdi-
agnosis of the disease. Consequently, if the
patients have fewer symptoms they will be
less diagnosed and less treated. On the other
hand, the patients were asked if they had
used any medication over the previous year
and not if these medications had been pre-
scribed by a physician. So, it was impossible
to know if medication was prescribed and
had not been taken by the patient. Self-
medication is a common practice in Brazil,
which makes it impossible to know, with the
tools used in this study, at what point there
was failure of the pharmacological treat-
ment.
The main limitation of the present study
is the spirometry criterion for COPD diag-
nosis, since severe asthmatic individuals and
those over 70 years of age may present an
FEV1/FVC ratio lower than 0.7. However, it
is not possible to differentiate asthma and
COPD in an individual over 40 years old by
spirometry alone (34-36), although the use
of the post-bronchodilator spirometry value
is supposed to reduce the false-positive cases.
However, the spirometry criterion adopted
in our study is the one most commonly de-
scribed in the COPD documents (9,10) and
used in epidemiological studies (37-39) and
allows us to compare our results to those of
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other studies. These patients were not ex-
cluded from the sample because, for COPD
epidemiological studies, the international
criterion for a diagnosis of COPD is a post-
bronchodilator FEV1/FVC ratio lower than
0.7 (9,10,14). The adoption of this criterion
definitely involves the risk of including asth-
matics or normal aged people. However, we
should point out that spirometry was per-
formed after the inhalation of a bronchodila-
tor, which is the routine test used to exclude
all mild and moderate asthmatics. Besides, it
is a consensus that the final individual diag-
nosis of asthma should always be made on a
clinical basis. This fixed ratio criterion should
be seen as a tool for population screening.
This diagnostic criterion is recommended by
the GOLD guidelines and has become the
most widely used one due to its feasibility
and better capacity for increasing the diag-
nosis of COPD.
This study demonstrated that COPD is
underdiagnosed and undertreated in Brazil.
These facts can generate higher impact to
COPD patients such as higher morbidity and
mortality and higher lung function rate de-
cline. A better screening program is needed
to improve the treatment of these patients
and to reduce the impact of the disease in
their lives.
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